JPMorgan Chase & Co. Issues Positive Forecast for McKesson (NYSE:MCK) Stock Price

McKesson (NYSE:MCK) had its price target boosted by JPMorgan Chase & Co. from $983.00 to $1,107.00 in a research note released on Tuesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Several other analysts have also issued reports on the stock. Barclays started coverage on shares of McKesson in a research report on Monday, December 8th. They issued an “overweight” rating and a $960.00 target price on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of McKesson in a report on Wednesday, December 10th. UBS Group increased their target price on McKesson from $920.00 to $980.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Evercore restated an “outperform” rating and issued a $1,000.00 target price on shares of McKesson in a research report on Thursday, November 6th. Finally, Zacks Research cut McKesson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $937.07.

McKesson Trading Down 2.9%

Shares of MCK stock opened at $934.41 on Tuesday. McKesson has a 12-month low of $585.22 and a 12-month high of $971.93. The business’s 50 day moving average is $832.63 and its two-hundred day moving average is $783.87. The company has a market capitalization of $114.46 billion, a P/E ratio of 26.87, a P/E/G ratio of 1.55 and a beta of 0.40.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. During the same period in the previous year, the business earned $8.03 earnings per share. The business’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, research analysts predict that McKesson will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, March 2nd. McKesson’s payout ratio is presently 9.43%.

Insider Buying and Selling

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the firm’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $955.00, for a total transaction of $313,240.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Thomas L. Rodgers sold 276 shares of McKesson stock in a transaction on Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president owned 2,268 shares in the company, valued at $1,851,096.24. This represents a 10.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is owned by company insiders.

Institutional Trading of McKesson

Institutional investors and hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC lifted its holdings in shares of McKesson by 46.3% in the 4th quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock worth $1,438,000 after acquiring an additional 798 shares during the last quarter. Caxton Associates LLP purchased a new stake in McKesson in the first quarter valued at approximately $233,000. Sivia Capital Partners LLC lifted its stake in McKesson by 77.9% during the second quarter. Sivia Capital Partners LLC now owns 685 shares of the company’s stock worth $502,000 after purchasing an additional 300 shares in the last quarter. Concurrent Investment Advisors LLC boosted its position in shares of McKesson by 11.9% during the second quarter. Concurrent Investment Advisors LLC now owns 1,987 shares of the company’s stock worth $1,456,000 after buying an additional 211 shares during the period. Finally, CWM LLC grew its stake in shares of McKesson by 5.7% in the second quarter. CWM LLC now owns 14,614 shares of the company’s stock valued at $10,709,000 after buying an additional 792 shares in the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: JPMorgan upgraded MCK to “Overweight” and raised its price target from $983 to $1,107, implying notable upside vs. recent levels — this is a clear bullish catalyst for investor demand. Benzinga
• Positive Sentiment: High-profile media/TV support (Jim Cramer praising McKesson) can boost retail interest and short-term buying flows. Cramer piece
• Positive Sentiment: Recent earnings beat and FY26 EPS guidance (38.80–39.20) plus a new quarterly dividend ($0.82/share) support the fundamental bull case for long-term investors. MarketBeat summary
• Neutral Sentiment: McKesson is attracting investor attention on screens (Zacks notes it’s among most-watched stocks), which can increase volatility but doesn’t itself imply direction. Zacks
• Neutral Sentiment: Coverage on automation and robotics (could improve logistics/efficiency long term) highlights an operational upside but is speculative for near-term earnings. Pharma-Technology
• Negative Sentiment: Insider selling: CAO Napoleon Rutledge Jr. sold 328 shares (filed with SEC) — small in size relative to the company but often interpreted negatively by some investors. InsiderTrades
• Negative Sentiment: McKesson reported flat revenues in its Medical‑Surgical segment, which may concern investors focused on near-term organic growth and margin leverage. HME News

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.